

## Cisplatin and Vinorelbine in unresectable malignant pleural mesothelioma

*Nivine M.A. Gado*

PAJO, December 2009, 2(4): 20-23

### **Abstract**

**Objective:** To evaluate the activity of cisplatin and vinorelbine as a first line, in unresectable patients with malignant pleural mesothelioma.

**Patients & Methods:** The study included 48 patients [77%- males] epithelial subtype (73%), stage III (43%), and stage IV (52%), performance status 0, 1 and 2, 23, 73 and 4%, respectively. The median age was 57 years [22 – 65 years]. Vinorelbine 25 mg/m<sup>2</sup> I.V. weekly and cisplatin 100 mg/m<sup>2</sup> I.V. every 4 weeks were given with hydration and antiemetic treatment.

**Results:** Median number of administered cycles was four. Objective response were observed in 29.2 % with no complete response Median time to progression was 7.8 months (1.8 – 40.2 months) and median survival 17.2 months (0.6 – 43 months). There were 14 PR (response rates 29.2%). The fraction of patients alive at 1 and 2 years were 62.5 and 31% respectively. Grade 3 or 4 leucopenia occurred in 33% and 11% of patients respectively, nausea in 10%, neurotoxicity in 12%, nephrotoxicity in 4%. There were no toxic deaths.

**Conclusion:** Cisplatin and vinorelbine is an active regimen in malignant pleural mesothelioma with a response rate and survival comparable to the most active regimens so far reported.